Focused Ultrasound-Enhanced Delivery of Intranasally Administered Anti-Programmed Cell Death-Ligand 1 Antibody to an Intracranial Murine Glioma Model

Immune checkpoint inhibitors have great potential for the treatment of gliomas; however, their therapeutic efficacy has been partially limited by inability to efficiently cross blood–brain barrier (BBB). The objective this study was evaluate capability focused-ultrasound-mediated intranasal brain drug delivery (FUSIN) in achieving locally enhanced anti-programmed cell death-ligand 1 antibody (aPD-L1) brain. Both non-tumor mice and transcranially implanted with GL261 glioma cells at brainstem were used study. aPD-L1 labeled a near-infrared fluorescence dye (IRDye 800CW) administered through nasal route brain, followed focused ultrasound sonication presence systemically injected microbubbles. FUSIN accumulation FUS-targeted an average 4.03- 3.74-fold compared (IN) administration alone mice, respectively. Immunohistochemistry staining found that mainly located within perivascular spaces after IN delivery, while further penetration depth efficiency parenchyma. delivered be colocalized tumor glioma. These findings suggest is promising technique enhance immune gliomas.